Pharsight

Qbrelis generic

Qbrelis is an anti-hypertensive drug owned by Azurity that got its market authorization on 29 July 2016. It contains an active ingredient called lisinopril and comes in a solution form for oral intake. Currently, Qbrelis holds nine active patents.

When will Qbrelis generic be available?

The generics of Qbrelis are expected to be released on the market after 6 November 2035, marking the expiry date of the last patent. This allows for a possible Qbrelis generic availability in the future.

Qbrelis uses

Qbrelis is widely used for the treatment of various cardiovascular disorders such as acute myocardial infarction, heart failure, and hypertension. The active ingredient, lisinopril, contributes to its effectiveness by helping to relax blood vessels, thus lowering blood pressure and improving heart function.

Qbrelis patent expiration

Qbrelis is protected by nine active patents, with the last one set to expire on 6 November 2035. The generics of Qbrelis can potentially be introduced to the market after this date. Below are the details of the patents:

Litigations filed on Qbrelis

Qbrelis dosage

Want to ask something?